FLT3 and acute myeloid leukemia: Newly diagnosed AML patients positive for FLT3-internal-tandem-duplication treated with quizartinib experienced a significantly improved OS compared to placebo treatment (quizartinib treated 32% n = 268 vs. placebo 15% n = 271; p = 0.032 NCT02668653) [91].